NNVC

Nanoviricides

• TipRanks·3h ago

  NanoViricides says NV-387 demonstrates ‘strong’ parameters in animal model study

• Benzinga·3h ago

  NanoViricides Announces That NV-387 Successfully Demonstrated Strong Safety, Tolerability, And Toxicological Parameters In An Animal Model Study Involving Juvenile Mouse Pups

• TipRanks·10/13 13:01

  NanoViricides announces Phase IIA Ebola trial of NV-387 is progressing well

• Benzinga·10/13 12:48

  NanoViricides Says Its Phase IIA Ebola Treatment Clinical Trial Of NV-387 Oral Gummies Is Progressing Well

• TipRanks·10/05 12:50

  NanoViricides says Phase II trial of NV-387 in ebola ‘proceeding as designed’

• Benzinga·10/05 12:49

  NanoViricides Updates Phase II Trial Of NV-387 Oral Gummies For Ebola Treatment In DRC; Reports Cautious Early Enrollment

• TipRanks·09/29 12:56

  NanoViricides ‘actively exploring’ additional required funding

• TipRanks·09/29 12:50

  NanoViricides reports FY26 EPS (41c) vs. (63c) last year

• Benzinga·09/28 21:47

  Nanoviricides Q4 EPS $(0.10), Inline

• TipRanks·09/28 12:55

  NanoViricides says Phase II trial of NV-387 in ebola starts enrollment, dosing

• TipRanks·09/24 13:30

  Analysts Offer Insights on Healthcare Companies: NanoViricides (NNVC) and Ionis Pharmaceuticals (IONS)

• Benzinga·09/21 17:06

  12 Health Care Stocks Moving In Monday's Intraday Session

• TipRanks·09/15 13:30

  NanoViricides to begin Phase II trial of NV-387 in ebola next week

• Benzinga·09/15 13:28

  NanoViricides Announces That Its Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In Democratic Republic Of Congo Is Scheduled To Begin Next Week

• TipRanks·09/08 12:45

  NanoViricides announces registration of Phase II trial of NV-387 in ebolavirus